Investment analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of NASDAQ EVOK opened at $4.24 on Tuesday. The stock’s 50-day moving average is $5.17 and its two-hundred day moving average is $5.96. The company has a market cap of $36.45 million, a price-to-earnings ratio of -2.32 and a beta of 0.38. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $18.60.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The firm had revenue of $2.55 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- How Much Can You Make in Stocks in One Month?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- This Is the Top Large-Cap Stock Insiders Are Buying
- What Are the U.K. Market Holidays? How to Invest and Trade
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
